Legal Opinion
Tris Pharma, Inc. v. Actavis Laboratories FL, Inc.
District Court, D. Delaware
Decided September 5, 2017No. C.A. No. 14-1309-GMSPublished
1Opinion of the Court
MEMORANDUM
Gregory M. Sleet, UNITED STATES DISTRICT JUDGE
I.INTRODUCTION
In this Hatch-Waxman patent infringement action, plaintiff Tris Pharma, Inc. (“Tris”) alleges patent infringement by de- ■ fendant Actavis Laboratories FL, Inc. (“Actavis”).. Plaintiff alleges that, by filing Abbreviated New Drug Applications (“AN-DAs”) seeking approval to market generic versions of Quillivant XR®, Defendant infringed U.S. Patent Nos. 8,46,765 (“the ’765 patent”), 8,563,033 (“the ’033 patent”), 8,778,390 (“the ’390 patent”), 8,956,649 (“the ’649 patent”), 9,040,083 (“the ’083 patent”). The court held a…
2Cases cited27 opinions
- Graham v. John Deere Co. of Kansas CitySupreme Court of the United States · 1966
- KSR International Co. v. Teleflex Inc.Supreme Court of the United States · 2007
- Colorado v. New MexicoSupreme Court of the United States · 1984
- Pfizer, Inc. v. Apotex, Inc.Court of Appeals for the Federal Circuit · 2007
- Muniauction, Inc. v. Thomson Corp.Court of Appeals for the Federal Circuit · 2008
22 more not listed; retrieve them via the Exa API.